���构特征与受体作用机制 — 2026 Update

By Editorial Desk · published 2026-02-27 · last reviewed 2026-04-06 · News

The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Background and Drug Class

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Semaglutide at a glance

Mechanism and Pharmacological Class

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Related pages on this site

• Tracked notes
• Practical review
• Simple guide
• Modular handbook
• Tracked review
• Simple playbook
• Automated reference
• Verified reference

Background and Mechanism of Action

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.

Semaglutide Structure and Receptor Mechanism

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Background and Molecular Design

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Supporting material

When bacteria grow in anaerobic environments, the terminal electron acceptor is reduced by an enzyme called a reductase. E. coli can use fumarate reductase, nitrate reductase, nitrite reductase, DMSO reductase, or trimethylamine-N-oxide reductase, depending on the availability of these acceptors in the environment. Most terminal oxidases and reductases are inducible. They are synthesized by the organism as needed, in response to specific environmental conditions.

=== Calcium and calmodulin dependence === The sensitivity of the CaMKII enzyme to calcium and calmodulin is governed by the variable and self-associative domains. This sensitivity level of CaMKII will also modulate the different states of activation for the enzyme. Initially, the enzyme is activated; however, autophosphorylation does not occur because there is not enough calcium or calmodulin present to bind to neighboring subunits. As greater amounts of calcium and calmodulin accumulate, autophosphorylation occurs leading to persistent activation of the CaMKII enzyme for a short period of time. However, the Threonine 286 residue eventually becomes dephosphorylated, leading to inactivation of CaMKII.

Among the challenges being faced to improve the efficiency of LED-based white light sources is the development of more efficient phosphors. As of 2010, the most efficient yellow phosphor is still the YAG phosphor, with less than 10% Stokes shift loss. Losses attributable to internal optical losses due to re-absorption in the LED chip and in the LED packaging itself typically account for another 10% to 30% loss. Currently, in the area of phosphor LED development, much effort is being spent on optimizing these devices to higher light output and higher operation temperatures. For instance, the efficiency can be raised by adapting better package design or by using a more suitable type of phosphor. Conformal coating process is frequently used to address the issue of varying phosphor thickness. Some phosphor-based white LEDs encapsulate InGaN blue LEDs inside phosphor-coated epoxy. Alternatively, the LED might be paired with a remote phosphor, a preformed polycarbonate piece coated with the phosphor material. Remote phosphors provide more diffuse light, which is desirable for many applications. Remote phosphor designs are also more tolerant of variations in the LED emissions spectrum. A common yellow phosphor material is cerium-doped yttrium aluminium garnet (Ce3+:YAG). White LEDs can also be made by coating near-ultraviolet (NUV) LEDs with a mixture of high-efficiency europium-based phosphors that emit red and blue, plus copper and aluminium-doped zinc sulfide (ZnS:Cu, Al) that emits green. This is a method analogous to the way fluorescent lamps work.

=== Energy source === Anabolism is powered by catabolism, where large molecules are broken down into smaller parts and then used up in cellular respiration. Many anabolic processes are powered by the cleavage of adenosine triphosphate (ATP). Anabolism usually involves reduction and decreases entropy, making it unfavorable without energy input. The starting materials, called the precursor molecules, are joined using the chemical energy made available from hydrolyzing ATP, reducing the cofactors NAD+, NADP+, and FAD, or performing other favorable side reactions. Occasionally it can also be driven by entropy without energy input, in cases like the formation of the phospholipid bilayer of a cell, where hydrophobic interactions aggregate the molecules.

Sources: en.wikipedia.org

Supporting material

=== 2012–2018: Change in pace === He starred alongside former co-star Steve Carell in the Don Scardino-directed comedy film The Incredible Burt Wonderstone (2013). Carrey played Steve Gray, a dangerous street magician who overshadows the formerly successful magician Burt Wonderstone (played by Carell). The film was released in March 2013 to mixed reviews and underperformed significantly at the box office, grossing just over $27 million on a $30 million budget. Around the same time, he appeared in Kick-Ass 2 (also 2013) as Colonel Stars and Stripes. He retracted support for the film two months prior to its release. He issued a statement via his Twitter account that, in light of the Sandy Hook Elementary School shooting, "Now in all good conscience I cannot support that level of violence." Peter Farrelly said in April 2012 that Carrey and Jeff Daniels would return for a Dumb and Dumber sequel, Dumb and Dumber To, with the Farrelly brothers writing and directing and a planned September 2012 production start. In June, however, Carrey's representative said Carrey had left the project because the comedian felt New Line and Warner Bros. were unenthusiastic toward it. However, on October 1, 2012, Yahoo!'s The Yo Show carried the news item that the script was complete and that the original actors, Carrey and Daniels, would be reprising their roles. The plot involved one of the characters having sired a child and needing to find them to obtain a kidney. Dumb and Dumber To was released in November 2014.

Because genome-wide data still separate the lineages, they remain distinct species even though their history cannot be depicted by a simple bifurcating tree. Keuler and colleagues recommend routine hybridisation tests (e.g., gene-tree comparison, HybridDetective) in intensive delimitation projects. Overall, such studies highlight how cryptic and dynamic lichen species can be, and they continue to drive up recognized species numbers.

=== Scientific research === Liquid argon is used as the target for neutrino experiments and direct dark matter searches. The interaction between the hypothetical WIMPs and an argon nucleus produces scintillation light that is detected by photomultiplier tubes. Two-phase detectors containing argon gas are used to detect the ionized electrons produced during the WIMP–nucleus scattering. As with most other liquefied noble gases, argon has a high scintillation light yield (about 51 photons/keV), is transparent to its own scintillation light, and is relatively easy to purify. Compared to xenon, argon is cheaper and has a distinct scintillation time profile, which allows the separation of electronic recoils from nuclear recoils. On the other hand, its intrinsic beta-ray background is larger due to 39Ar contamination, unless one uses argon from underground sources, which has much less 39Ar contamination. Most of the argon in Earth's atmosphere was produced by electron capture of long-lived 40K (40K + e− → 40Ar + ν) present in natural potassium within Earth. The 39Ar activity in the atmosphere is maintained by cosmogenic production through the knockout reaction 40Ar(n,2n)39Ar and similar reactions. The half-life of 39Ar is only 269 years. As a result, the underground Ar, shielded by rock and water, has much less 39Ar contamination. Dark-matter detectors currently operating with liquid argon include DarkSide, WArP, ArDM, microCLEAN and DEAP.

Sources: en.wikipedia.org

Notes from published material

==== Structure ==== A eukaryotic cell has a cell membrane that surrounds a gel-like cytoplasm. The cytoplasm contains the cytoskeleton, the cell nucleus, the endoplasmic reticulum, ribosomes, the Golgi apparatus, mitochondria, peroxisomes, endosomes, vacuoles and vesicles, and vaults. A eukaryotic cell structure, includes an endomembrane system encompassing the cell membrane, and all the membranes of the organelles excluding those of the mitochondria. The whole system cooperates in the modification, packaging, and transport of proteins and lipids.

=== Biscuits company === In 1938, Lyons purchased the Bee Bee Biscuit Company, which manufactured biscuits from its factories in Blackpool. Six years later, Lyons changed the company's name to Symbol Biscuits Ltd. and began selling biscuits under the Symbol and Lyons brand names: one of their innovations was Maryland Cookies in 1956. In 1990, Lyons changed the Symbol Biscuits name to Lyons Biscuits Ltd.

== Professor of Pathology and Head of Department Chronology == The Professor of Pathology is an established (statutory) chair at the University of Cambridge which was established in 1883. Traditionally, the Professor of Pathology was also the formal Head of department. However, in 2023 Professor Adrian Liston was elected to the Professor of Pathology while Professor Heike Laman was elected 10th Head of department and became the first woman to take on the role since the founding of the department in 1883.

Additionally, H-DNA has been shown to cause mutations related to critical cellular processes like DNA replication and transcription. The importance of these processes for survival has led to the development of complex DNA repair mechanisms that allow cells to recognize and fix DNA damage. Non-canonical DNA structures can be perceived as damage by the cell, and recent work has shown an increased prevalence of mutations near non-B-DNA-forming sequences. Some of these mutations are due to the interactions between H-DNA and the enzymes involved in DNA replication and transcription, where H-DNA interferes with these processes and triggers various DNA repair mechanisms. This can cause genetic instability and implicates H-DNA in cancer formation.

Sources: en.wikipedia.org

Frequently asked questions